(Q44583582)

4 December 2017

0 references

Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients (English)

1 reference

4 December 2017

0 references

Connie B Newman

1

1 reference

4 December 2017

Gary Palmer

series ordinal

2

1 reference

4 December 2017

Halit Silbershatz

series ordinal

3

1 reference

4 December 2017

Michael Szarek

series ordinal

4

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

American Journal of Cardiology

4 December 2017

published in

1 reference

4 December 2017

volume

92

1 reference

4 December 2017

issue

6

1 reference

4 December 2017

page(s)

670-676

1 reference

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Current perspectives on statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Statin-associated myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Learning from the cerivastatin experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Frequency of creatine kinase elevation during treatment with fluvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900820-8

10.1016/S0002-9149(03)00820-8

7 January 2021

Identifiers

DOI

1 reference

4 December 2017

1 reference